PA8481901A1 - Administracion de agente activo en polvo seco - Google Patents

Administracion de agente activo en polvo seco

Info

Publication number
PA8481901A1
PA8481901A1 PA19998481901A PA8481901A PA8481901A1 PA 8481901 A1 PA8481901 A1 PA 8481901A1 PA 19998481901 A PA19998481901 A PA 19998481901A PA 8481901 A PA8481901 A PA 8481901A PA 8481901 A1 PA8481901 A1 PA 8481901A1
Authority
PA
Panama
Prior art keywords
active agent
administration
dry powder
inhibitor
hygroscopic growth
Prior art date
Application number
PA19998481901A
Other languages
English (en)
Inventor
Barry John Aldous
Andrew Clark
Kuo Mei Chang
Cecily Lalor
Original Assignee
Inhale Therapeutic Syst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhale Therapeutic Syst filed Critical Inhale Therapeutic Syst
Publication of PA8481901A1 publication Critical patent/PA8481901A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

PARTICULAS PARA LA ADMINISTRACION DE UN AGENTE ACTIVO A LOS ALVEOLOS DE UN PACIENTE HUMANO, PARTICULAS QUE CONTIENEN EL AGENTE ACTIVO Y UN INHIBIDOR DEL CRECIMIENTO HIGROSCOPICO, DONDE EL INHIBIDOR DEL CRECIMIENTO HIGROSCOPICO ESTA INCORPORADO AL INTERIOR DE LAS PARTICULAS Y DONDE LAS PARTICULAS EXHIBEN UNA CAIDA DE LA DOSIS EMITIDA, EN CONDICIONES PULMONARES SIMULADAS, DE NO MAS DE APROXIMADAMENTE 25%.
PA19998481901A 1998-09-14 1999-09-14 Administracion de agente activo en polvo seco PA8481901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10016398P 1998-09-14 1998-09-14

Publications (1)

Publication Number Publication Date
PA8481901A1 true PA8481901A1 (es) 2002-04-25

Family

ID=22278404

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19998481901A PA8481901A1 (es) 1998-09-14 1999-09-14 Administracion de agente activo en polvo seco

Country Status (44)

Country Link
EP (1) EP1117442A1 (es)
JP (1) JP2002524535A (es)
KR (1) KR20010075063A (es)
CN (1) CN1317977A (es)
AP (1) AP1374A (es)
AR (1) AR022090A1 (es)
AU (1) AU753014B2 (es)
BG (1) BG105430A (es)
BR (1) BR9913722A (es)
CA (1) CA2343920A1 (es)
CO (1) CO5130023A1 (es)
CZ (1) CZ2001829A3 (es)
DZ (1) DZ2892A1 (es)
EA (1) EA003476B1 (es)
EE (1) EE200100151A (es)
GE (1) GEP20043257B (es)
GT (1) GT199900156A (es)
HK (1) HK1042231A1 (es)
HN (1) HN1999000159A (es)
HR (1) HRP20010189A2 (es)
HU (1) HUP0103837A3 (es)
ID (1) ID28845A (es)
IL (2) IL141562A0 (es)
IS (1) IS5878A (es)
LT (1) LT4897B (es)
LV (1) LV12658B (es)
MA (1) MA25590A1 (es)
MY (1) MY129282A (es)
NO (1) NO20011251L (es)
NZ (1) NZ510168A (es)
OA (1) OA11781A (es)
PA (1) PA8481901A1 (es)
PE (1) PE20001061A1 (es)
PL (1) PL195574B1 (es)
SA (1) SA99200718B1 (es)
SK (1) SK3442001A3 (es)
TN (1) TNSN99173A1 (es)
TR (1) TR200101182T2 (es)
TW (1) TWI226248B (es)
UA (1) UA76085C2 (es)
UY (1) UY25711A1 (es)
WO (1) WO2000015262A1 (es)
YU (1) YU24201A (es)
ZA (1) ZA200101995B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4874483B2 (ja) 1999-06-09 2012-02-15 ロバート イー． シーバース 超臨界流体補助ネブライゼーション及びバブル乾燥
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
JP2005503425A (ja) * 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
JP2005518453A (ja) 2002-02-25 2005-06-23 ディフュージョン・ファーマシューティカルズ・エルエルシー 二極性トランスカロテノイド塩およびそれらの使用
AU2003232081B2 (en) * 2002-07-03 2009-02-05 Brandeis University Central airway administration for systemic delivery of therapeutics
CA2511385A1 (en) * 2002-12-19 2004-07-22 Pharmacia Corporation Non-hygroscopic formulation comprising a hydroscopic drug
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
AU2005237523A1 (en) 2004-04-23 2005-11-10 Cydex Pharmaceuticals, Inc. DPI formulation containing sulfoalkyl ether cyclodextrin
EP2540696B1 (en) 2005-02-24 2020-01-01 Diffusion Pharmaceuticals LLC Trans carotenoids, formulation and uses
CN101171023A (zh) * 2005-03-09 2008-04-30 小野药品工业株式会社 一种粒子以及含有该粒子的制剂
DK2952197T3 (en) 2005-10-26 2017-08-07 Cydex Pharmaceuticals Inc SULPHALYCYLETER CYCLE CODE EXTRACTION COMPOSITION AND PROCEDURE FOR PREPARING THEREOF
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
WO2008021451A2 (en) * 2006-08-14 2008-02-21 Aktiv-Dry Llc Human-powered dry powder inhaler and dry powder inhaler compositions
EP2095812A4 (en) * 2006-10-25 2011-07-13 Dainippon Sumitomo Pharma Co NON-AGGLUTINANT GRANULAR PREPARATION
EP1925295A1 (de) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stabile Pulverformulierung enthaltend ein Anticholinergikum
KR101570131B1 (ko) 2007-04-13 2015-11-18 디퓨젼 파마슈티컬즈 엘엘씨 양극성 트랜스 카로티노이드의 말초혈관질환 치료와 예방을 위한 용도
JP2011502125A (ja) 2007-10-31 2011-01-20 ディフュージョン・ファーマシューティカルズ・エルエルシー 小分子拡散を促進する新しい種類の治療法
PL2432502T3 (pl) 2009-05-20 2018-05-30 Aeras Trwałe, suszone rozpyłowo, immunogenne kompozycje wirusowe
EP2445339B1 (en) 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Diffusion enhancing compound and its use with a thrombolytic
CN105287473A (zh) 2010-06-02 2016-02-03 扩散药品有限公司 包含双极性反式类胡萝卜素的组合物及其应用
RU2650636C2 (ru) 2012-05-03 2018-04-16 Янссен Сайенсиз Айрлэнд Юси Составы на основе полиинозиновой-полицитидиловой кислоты (poly(i:с)) для лечения инфекций верхних дыхательных путей
BR112015010601B1 (pt) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
US20180043585A9 (en) * 2013-09-20 2018-02-15 Virginia Commonwealth University Delivery of particles using hygroscopic excipients
EP3212212B1 (en) 2014-10-31 2020-09-23 Monash University Powder formulation
WO2017165667A1 (en) 2016-03-24 2017-09-28 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
US20220378727A1 (en) * 2021-05-14 2022-12-01 The University Of Hong Kong Dry powder formulations of tamibarotene for pulmonary and intranasal delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
ES2177544T3 (es) * 1992-06-12 2002-12-16 Teijin Ltd Polvo ultrafinno para inhalar y metodo para su preparacion.
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant

Also Published As

Publication number Publication date
AP2001002093A0 (en) 2001-03-31
BG105430A (en) 2001-12-29
WO2000015262A1 (en) 2000-03-23
ZA200101995B (en) 2002-03-11
CO5130023A1 (es) 2002-02-27
AP1374A (en) 2005-02-28
IS5878A (is) 2001-03-05
AR022090A1 (es) 2002-09-04
EA003476B1 (ru) 2003-06-26
YU24201A (sh) 2003-08-29
ID28845A (id) 2001-07-05
CN1317977A (zh) 2001-10-17
EA200100300A1 (ru) 2001-10-22
KR20010075063A (ko) 2001-08-09
GEP20043257B (en) 2004-06-25
LV12658A (lv) 2001-05-20
IL141562A (en) 2007-07-24
HK1042231A1 (zh) 2002-08-09
SA99200718B1 (ar) 2006-11-04
PE20001061A1 (es) 2000-10-08
EP1117442A1 (en) 2001-07-25
MA25590A1 (fr) 2002-12-31
LT2001021A (en) 2001-11-26
MY129282A (en) 2007-03-30
HUP0103837A3 (en) 2002-11-28
AU753014B2 (en) 2002-10-03
BR9913722A (pt) 2001-05-29
UA76085C2 (en) 2006-07-17
GT199900156A (es) 2001-03-07
SK3442001A3 (en) 2001-11-06
NO20011251L (no) 2001-04-17
LT4897B (lt) 2002-02-25
CZ2001829A3 (cs) 2001-09-12
UY25711A1 (es) 1999-11-17
NZ510168A (en) 2003-09-26
DZ2892A1 (fr) 2003-12-15
NO20011251D0 (no) 2001-03-13
IL141562A0 (en) 2002-03-10
JP2002524535A (ja) 2002-08-06
EE200100151A (et) 2002-06-17
AU6039799A (en) 2000-04-03
PL195574B1 (pl) 2007-10-31
TWI226248B (en) 2005-01-11
CA2343920A1 (en) 2000-03-23
PL346768A1 (en) 2002-02-25
HUP0103837A2 (hu) 2002-05-29
LV12658B (lv) 2001-09-20
HRP20010189A2 (en) 2005-04-30
HN1999000159A (es) 1999-11-11
OA11781A (en) 2005-07-26
TR200101182T2 (tr) 2001-09-21
TNSN99173A1 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
PA8481901A1 (es) Administracion de agente activo en polvo seco
CO5060522A1 (es) Administracion de un agente activo en aerosol
ES2159591T3 (es) Composicion de liberacion controlada.
GT200000041A (es) Uso de inhibidores de cyp2d6 en terapias de combinacion.
ES2073205T3 (es) Agentes con efecto refrigerante fisiologico y compuestos activos apropiados para estos agentes.
AR002754A1 (es) Composición farmacéutica que comprende bacterias lactobacillus viables micro-encapsuladas, y uso de la composición para preparar de un medicamento
CO4340681A1 (es) Procedimientos de uso para la inhibicion de la perdida osea y la disminucion del colesterol en suero
DE60027463D1 (de) Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon
ES2117015T3 (es) Composiciones que contienen sumatriptan.
ES2064121T3 (es) Agente para reducir o eliminar el crecimiento de los pelos del cuerpo humano.
MX9300620A (es) Formulacion farmaceutica en aerosol e inhalador para la administracion de dipropionato de beclometasona.
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
DE69620606D1 (de) Feste oral anzuwendende arzeneiform
BR0311460A (pt) Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
BR0313148A (pt) Formulações de liberação controlada compreendendo lamotrigina
NO951498L (no) Farmasöytisk preparat for behandling av osteoporose
ES2184145T3 (es) Compuestos de acido sulfonico o sulfonilamino-n-(heteroaralquil)-azaheterociclilamida.
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
CN111214689A (zh) 一种高效预防新型冠状病毒肺炎和流感的香囊
ES2179960T3 (es) Solucion de conservacion para organos o tejidos, o partes de los mismos, de seres humanos o animales.
EA200200151A1 (ru) Сухая порошкообразная композиция
CO5580741A2 (es) Composicion farmaceutica que comprende un agonista de receptor de 5ht1
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4
ES2131863T3 (es) Derivados de colchicina y su uso terapeutico.